Filter: All News Events
12.07.2017

Long-term outcomes after standard graft-versus-host disease (GvHD) prophylaxis in hemopoietic cell transplantation from matched unrelated donors strongly support the use of Grafalon® (anti-human-T-lymphocyte immunoglobulin) as standard therapy

14.09.2016

Neovii Pharmaceuticals AG licenses worldwide (excluding U.S. & Japan) developmental and commercialization rights for ARCALYST® (rilonacept) from Regeneron for the treatment of periodic fever syndromes

14.01.2016

European study in patients with acute leukemia shows the inclusion of Grafalon® (anti T-lymphocyte immunoglobulin) in a conditioning regimen before stem cell transplantation from HLA-identical siblings results in a significantly lower incidence of chronic GvHD.